A method for implanting a medical device for lubricating a joint in a human body, said method comprising the steps of creating an opening reaching from outside of the human body into the joint, providing an artificial contacting surface to said joint, fixating the artificial contacting surface to the joint, implanting a reservoir in the human body, and lubricating said artificial contacting surface by pressurizing a lubricating fluid contained in said reservoir.

An embodiment includes a vascular port comprising: first and second portions that are not monolithic with each other; wherein: (a)(i) the first portion includes a first arcuate surface to contour to a first portion of a vessel and the second portion includes a second arcuate surface to contour to a second portion of the vessel; (a)(ii) the first and second portions couple to one another around the vessel when implanted to form a central chamber that houses the vessel; (a)(iii) the first portion includes a port that includes a funnel with a funnel surface that narrows as the funnel surface approaches the central chamber; (a)(iv) the central chamber includes a central longitudinal axis and the funnel includes a central vertical axis that is orthogonal to the longitudinal axis; (a)(v) the second portion includes a hardened, non-compliant surface that intersects the vertical axis.

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.

A platelet-rich fibrin (PRF) three-dimensional, adhesive, biocompatible and biodegradable scaffold and/or membrane is obtained by collecting a blood sample, followed by centrifugation of the blood sample to obtain a platelet-rich fibrin clot and an exudate followed by compressing platelet-rich fibrin clot to extract the exudate until the final product being a platelet-rich fibrin three-dimensional, adhesive, biocompatible and biodegradable scaffold is obtained. A hyper-acute serum is obtained by collecting a blood sample, followed by centrifugation of said blood sample to obtain a platelet-rich fibrin clot and an exudate followed by compressing platelet-rich fibrin clot to obtain the membrane and extract the exudate being the final product hyper-acute serum. A process for the preparation of a platelet-rich fibrin three-dimensional, adhesive, biocompatible and biodegradable scaffold and/or membrane and a hyper-acute serum is also provided. A method for the treatment of inguinal hernia in a patient in need thereof is also provided.

A biologic material is disclosed. The biologic material comprises a crosslinked structural protein and macrophages seeded on the crosslinked structural protein. A method of use of the biologic material for an immunoregenerative treatment in a patient in need thereof also is disclosed. The method comprises steps of: (1) seeding the macrophages on the crosslinked structural protein, thereby obtaining the biologic material; and (2) implanting the biologic material into the patient.

The present invention is a specially prepared fibrin foam, and a method of (and equipment for) making it, which is flexible, contains either open cells, closed cells or both, and having individual cell diameters between 0.001 and 2 mm. Typical ratios of reactants, to give the desired foam characteristics, include 50 cc (45-55 cc) of whole blood (prior to separation to the plasma component) with the subsequent addition thereto of 2 ml (1.5-2.5 ml) 3% hydrogen peroxide, 5000 units (4500-5500 units) thrombin and 1 gm (0.9-1.1 g) calcium chloride in 3 cc (2-4 cc) water. The present invention also includes specialty vessels and constructs, namely, automated, or semi-automated inner containers for the non-blood reactants, and a custom outer separation vessel having a punted based with an annular base lip as well as an upper tube shape tapering inward towards its top annular opening.

Provided herein relates to high molecular weight silk-based materials, compositions comprising the same, and processes of preparing the same. The silk-based materials produced from high molecular weight silk can be used in various applications ranging from biomedical applications such as tissue engineering scaffolds to construction applications. In some embodiments, the high molecular weight silk can be used to produce high strength silk-based materials. In some embodiments, the high molecular weight silk can be used to produce silk-based materials that are mechanically strong with tunable degradation properties.

An implantable medical device for implantation in a mammal joint having at least two contacting surfaces is provided. The medical device comprises; an artificial contacting surface adapted to replace at least the surface of at least one of the mammal's joint contacting surfaces, wherein the artificial contacting surface is adapted to be lubricated, when implanted in said joint. Furthermore the medical device comprises at least one inlet adapted to receive a lubricating fluid from a reservoir, at least one channel at least partly integrated in the artificial contacting surface in connection with the at least one inlet for distributing the lubricating fluid to the surface of the artificial contacting surface. The medical device could be adapted to be operable by an operation device to receive the distributed lubricated fluid from a reservoir.

Embodiments herein relate to active agent depots formed in situ and related methods. In various embodiments, a method of forming an active agent depot in situ is included. The method can include contacting a composition with a vessel wall, wherein the composition includes an active agent and a fibrin promoting vessel wall transfer agent wherein the ratio of active agent to fibrin promoting vessel wall transfer agent (wt./wt.) is at least 5:1. The method also includes transferring the composition from a device surface to the vessel wall surface. The method also includes forming a fibrin matrix around the composition. Other embodiments are also included herein.

A method of production of a tissue sealing patch is disclosed. The method comprises casting a polymer film from a biocompatible polyethylene glycol-caprolactone-lactide triblock copolymer (PECALA); softening the polymer film; placing a powdered tissue sealant material on a surface of said polymer film; and, pressing said polymer film to at least partially incorporate the sealant material into said surface of said polymer film. In some embodiments of the invention, the polymer film is created by heating and evacuating a work surface; applying a solution of PECALA to said work surface; adjusting a polymer blade to a predetermined height above said work surface; spreading said solution of PECALA over said work surface with said polymer blade; and evaporating said solvent. The PECALA preferably comprises PEG-CL-LA units connected by urethane linkages, PEG having a molecular weight of between 3000 and 3500 amu, and a CL:LA:PEG ratio of 34:2:1.